Journal article

Ability of the Encephalitic Arbovirus Semliki Forest Virus To Cross the Blood-Brain Barrier Is Determined by the Charge of the E2 Glycoprotein

Mhairi C Ferguson, Sirle Saul, Rennos Fragkoudis, Sabine Weisheit, Jonathan Cox, Adjanie Patabendige, Karen Sherwood, Mick Watson, Andres Merits, John K Fazakerley



UNLABELLED: Semliki Forest virus (SFV) provides a well-characterized model system to study the pathogenesis of virus encephalitis. Several studies have used virus derived from the molecular clone SFV4. SFV4 virus does not have the same phenotype as the closely related L10 or the prototype virus from which its molecular clone was derived. In mice, L10 generates a high-titer plasma viremia, is efficiently neuroinvasive, and produces a fatal panencephalitis, whereas low-dose SFV4 produces a low-titer viremia, rarely enters the brain, and generally is avirulent. To determine the genetic differences responsible, the consensus sequence of L10 was determined and compared to that of SFV4. Of the 12 ..

View full abstract


Awarded by Pirbright Institute

Awarded by Estonian Ministry of Education and Research

Awarded by Estonian Science Foundation

Awarded by NERC

Awarded by MRC

Awarded by BBSRC

Awarded by Biotechnology and Biological Sciences Research Council

Awarded by Medical Research Council

Awarded by National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)

Funding Acknowledgements

[ "This work was supported by Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Project Grants (ISPGs) at The Roslin Institute and The Pirbright Institute (BBB/E/I/00001735). This work was supported by institutional research funding (IUT20-27) from the Estonian Ministry of Education and Research, Estonian Science Foundation (grant 9400), and the European Union through the European Regional Development Fund via the Centre of Excellence in Chemical Biology.", "Sequencing was carried out by Edinburgh Genomics, The University of Edinburgh. Edinburgh Genomics is partly supported through core grants from NERC (R8/H10/56), MRC (MR/K001744/1), and BBSRC (BB/J004243/1)." ]